MDGED
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple so… Read more
MDGED (MDGED) - Net Assets
Latest net assets as of June 2024: $19.66 Million USD
Based on the latest financial reports, MDGED (MDGED) has net assets worth $19.66 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($28.81 Million) and total liabilities ($9.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $19.66 Million |
| % of Total Assets | 68.24% |
| Annual Growth Rate | -26.56% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 12.54 |
MDGED - Net Assets Trend (2020–2023)
This chart illustrates how MDGED's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MDGED (2020–2023)
The table below shows the annual net assets of MDGED from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $21.07 Million | -43.10% |
| 2022-12-31 | $37.03 Million | -17.38% |
| 2021-12-31 | $44.82 Million | -15.68% |
| 2020-12-31 | $53.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MDGED's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3448800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $507.26 Million | 2407.83% |
| Total Equity | $21.07 Million | 100.00% |
MDGED Competitors by Market Cap
The table below lists competitors of MDGED ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PIQUADRO
BE:4LZ
|
$24.49K |
|
ZAMBIA SUGAR PLC
LUSE:ZSUG
|
$24.49K |
|
WHARF (HLDGS)
MU:WHA
|
$24.50K |
|
BELLINI NAUTICA S.P.A.
F:F2F
|
$24.52K |
|
ECOMMERCE ALLIANCE
BE:ECF
|
$24.45K |
|
HISENSE KELON -H-
MU:GKE
|
$24.45K |
|
Innerscope Advertising Agency Inc
PINK:INND
|
$24.44K |
|
RIVER+MERC.UK MIC.RED PR
F:3RM0
|
$24.41K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MDGED's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 37,027,000 to 21,067,000, a change of -15,960,000 (-43.1%).
- Net loss of 16,177,000 reduced equity.
- Other factors increased equity by 217,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.18 Million | -76.79% |
| Other Changes | $217.00K | +1.03% |
| Total Change | $- | -43.10% |
Book Value vs Market Value Analysis
This analysis compares MDGED's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.18x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.26x to 3.18x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $2.05 | $2.59 | x |
| 2021-12-31 | $1.73 | $2.59 | x |
| 2022-12-31 | $1.43 | $2.59 | x |
| 2023-12-31 | $0.81 | $2.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MDGED utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -76.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -268.10%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.51x
- Recent ROE (-76.79%) is below the historical average (-43.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -54.32% | -360.85% | 0.11x | 1.41x | $-34.19 Million |
| 2021 | -22.28% | -95.41% | 0.18x | 1.33x | $-14.46 Million |
| 2022 | -22.50% | -26.66% | 0.60x | 1.40x | $-12.03 Million |
| 2023 | -76.79% | -268.10% | 0.19x | 1.51x | $-18.28 Million |
Industry Comparison
This section compares MDGED's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MDGED (MDGED) | $19.66 Million | -54.32% | 0.47x | $24.47K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |